Introduction of Procalcitonin Testing and Antibiotic Utilization for Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Robert J Ulrich1,2,3, Daniel McClung1,4, Bonnie R Wang1,5, Spencer Winters1,6, Scott A Flanders1 and Krishna Rao1,4

1Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, MI, USA. 2Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, USA. 3Division of Infectious Diseases and Immunology, NYU School of Medicine, New York, NY, USA. 4Division of Infectious Diseases, School of Medicine, University of Michigan, Ann Arbor, MI, USA. 5Division of Pulmonary and Critical Care, School of Medicine, University of Michigan, Ann Arbor, MI, USA. 6Division of Pulmonary, Allergy and Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

ABSTRACT

BACKGROUND: The majority of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are triggered by nonbacterial causes, yet most patients receive antibiotics. Treatment guided by procalcitonin (PCT), a sensitive biomarker of bacterial infection, safely decreases antibiotic use in many controlled trials. We evaluated PCT implementation for inpatients with AECOPD at a large academic hospital.

METHODS: All patients admitted for AECOPD during the first 6 months of PCT-guided therapy were eligible for inclusion in this retrospective cohort study. Patients with PCT performed were compared with those without PCT. The primary outcome was antibiotic days of therapy (DOT). Secondary outcomes included 30-day readmission and mortality.

RESULTS: Of the 238 AECOPD admissions, 73 (31%) had PCT performed. Procalcitonin-tested patients were more likely to meet systemic inflammatory response syndrome (SIRS) criteria, require intensive care unit (ICU)-level care, and have a longer length of stay (LOS) compared with those without PCT. Even after adjustment for these factors, PCT-tested patients received more inpatient DOT and there was no difference in total DOT. However, a low PCT value (<0.25 ng/mL) was associated with a 25.5% (P < .001) decrease in intravenous (IV) antibiotic DOT. Guideline-recommended follow-up testing was rare (12%). Procalcitonin measurement had no effect on 30-day readmission or mortality.

CONCLUSIONS: In this real-world analysis of inpatients with AECOPD, PCT-guided therapy was poorly adopted by providers and was not associated with a decrease in total antibiotic DOT. However, a low PCT level was associated with a 25.5% decrease in IV antibiotic DOT, suggesting increased comfort stepping down from IV to PO therapy.

KEYWORDS: COPD exacerbation, procalcitonin, antibiotics, respiratory infection

Introduction

Chronic obstructive pulmonary disease (COPD) affects 10% to 20% of Americans >40 years and is the third leading cause of death in the United States.1-4 Acute exacerbations of COPD (AECOPD), defined as acute worsening in baseline symptoms beyond normal daily variations, are associated with significant morbidity and mortality.3 When the exacerbation is severe enough to warrant admission, 85%-87% of patients receive antibiotics.4,5 Using antibiotics in severe AECOPD can decrease treatment failure and is consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.6,7 However, the majority of AECOPD may not be impacted by antibiotics; 22% are noninfectious and only 55% of infectious etiologies are bacterial.7

Overuse of antibacterial therapy is not without consequence. Selective pressure is a primary mechanism in creating resistant organisms.8 Specific to respiratory illness, broad spectrum antibiotics have been linked to methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus pneumoniae (MRSP), and fluoroquinolone-resistant Streptococcus pneumoniae.9-11 Furthermore, the intestinal dysbiosis from antibiotic therapy can nearly triple a
patient’s risk of all-cause diarrhea and predispose them to Clostridium difficile colitis, a nosocomial pathogen responsible for nearly 30,000 deaths per year.6,12,13

Considering the unintended consequences of antimicrobial therapy and the often nonbacterial cause of AECOPD, a specific biomarker for bacterial respiratory infections would be valuable. Procalcitonin (PCT)—a precursor peptide stimulated from bacteria-specific pro-inflammatory mediators (IL1-β, tumor necrosis factor [TNF], and interleukin [IL]-6)14—is such a biomarker.15 Since 2004, there have been multiple randomized trials and a Cochrane review showing that PCT-guided therapy safely reduces antibiotic exposure in acute respiratory illness (ARI).16-18 Specific to AECOPD, a decrease in antibiotic exposure was shown in a randomized trial (ProCOLD)19 and recent meta-analysis.20 From an economic standpoint, it has been estimated that widespread use of PCT-guided therapy in the United States in case of ARI could save US$1.6 billion annually.21

Although PCT-guided antibiotic therapy shows promise for safely reducing antimicrobial use in AECOPD, its utility is extrapolated from predominantly randomized, controlled settings outside of North America. As hospitals increasingly introduce PCT to help antibiotic decision making, it is important to understand whether the benefits are achievable in real-world settings.

Materials and Methods

Patients and study design

We conducted a retrospective analysis using electronic records at a large academic hospital in Ann Arbor, Michigan. Data were collected over the first 6 months of PCT availability (October 1, 2013–March 31, 2014). Institutional rollout of PCT testing included dissemination of institutional PCT guidelines (Figure 1) to department chairs, making the guidelines available online, and education by infectious diseases (ID) faculty at general medicine, surgery, and emergency department (ED) weekly conferences. Inpatients ≥18 years of age with an International Classification of Diseases, Ninth Revision22 (ICD-9) principal admission diagnosis of AECOPD were eligible and records were manually reviewed to confirm the diagnosis. Patients transferred from outside facilities were excluded. Requirement for patient consent was waived and the study was approved by the University of Michigan Health System Institutional Review Board (HUM00085581).

Measurements

In addition to standard demographic data, antibiotic days of therapy (DOT) and type (intravenous [IV] or oral) were recorded. Patients on chronic antibiotics (N = 6) at admission
were included, but days on chronic antibiotics were excluded. Days of therapy included antibiotics initiated in the emergency department or while inpatient. If a patient was discharged with outpatient antibiotics, the anticipated course based on prescriptions was added to inpatient DOT to give total DOT. Systemic inflammatory response syndrome (SIRS) criteria were defined in concordance with the American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) 1992 conference. Patients were classified into GOLD classes using forced expiratory volume in 1 second (FEV1) on prior pulmonary function testing (PFT) when available. Acute exacerbations of COPD within the last year and home oxygen use was determined with detailed record review. Procalcitonin measurement was at the discretion of the admitting and inpatient physicians. Procalcitonin was performed from 0.5 mL of serum using the VIDAS BRAHMS assay (bioMérieux, Inc., Durham, NC, USA), a US Food and Drug Administration (FDA)-approved automated immunofluorescent assay. Procalcitonin was considered low if ≤0.25 ng/mL. When PCT was performed, time to re-testing was compared with institutional protocol (Figure 1).

**Outcomes**

Our primary outcome is antibiotic DOT. Secondary outcomes include protocol re-testing compliance, length of stay (LOS), 30-day readmission, and mortality.

**Statistics**

All analyses were conducted in R, version 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). Variables were examined for out-of-range values and histograms were used to visualize continuous variables. Descriptive statistics included proportions for categorical variables and measures of central tendency/spread for continuous variables. These initial analyses assisted in reconstructing variables for analysis, including logarithmic transformations for DOT and LOS due to the non-normal distribution of data points. P-values <.05 were considered statistically significant for all analyses. To analyze relationships between predictor variables and the primary/secondary outcomes, simple linear or logistic regression was employed. Multiple linear or logistic regression models were employed for adjusted analysis and variables were included in the final models based on significance on unadjusted analysis. Backwards elimination was then employed to result in a final candidate model. Interactions were modeled and included if significant.

**Results**

**PCT testing and outcomes**

A total of 238 patients were admitted with AECOPD during the study period: 73 (31%) had PCT testing and 165 (69%) did not (Table 1). There were no significant age or gender differences between the 2 groups. Prior PFTs were available in 160 (67%) patients with no significant differences in FEV1 or GOLD classification. On unadjusted analysis, patients with PCT testing during the admission were more likely to be admitted to the intensive care unit (ICU; odds ratio [OR]: 2.21, 95% confidence interval [CI]: 1.02–4.81, P = .042), meet SIRS criteria (OR: 1.5, 95% CI: 1.09–2.06, P = .012), and have a baseline home oxygen requirement (OR: 2.24, 95% CI: 1.28–3.92, P = .005). In total, 171 (72%) patients received antibiotics while inpatient. Patients who underwent PCT testing were more likely to receive antibiotic therapy (OR: 3.85, 95% CI: 1.79–8.3, P = .001) and receive IV antibiotics (OR: 2.7, 95% CI: 1.51–4.8, P = .001), and these associations held after adjustment for the presence of SIRS and LOS. Procalcitonin testing had no effect on discharge antibiotic prescription rates (P = .493). On average, patients with PCT testing were admitted longer (5.4 ± 3.8 vs 3.1 ± 3.3; P < .001) and had more inpatient DOT (2.8 ± 1.8 vs 2.0 ± 1.4; P < .001) than those without PCT. Despite the differences in inpatient antibiotic DOT, PCT measurement had no effect on total DOT (P = .140; Figure 2). Only 9 (12%) patients with PCT testing had guideline-recommended re-testing. There was no difference in 30-day mortality (P = .213) or readmission (P = .514) after adjusting for LOS.

**PCT level and outcomes**

Patients with PCT testing were further divided into groups with low (≤0.25 ng/mL) and high (>0.25 ng/mL) results; 57 (78%) of PCT results were low. All 16 patients with high PCT results received antibiotics, and 48 of 57 (84.2%) patients of the low PCT results received antibiotics. Despite high antibiotic imitation regardless of PCT level, a low PCT result was associated with a 27.2% lower (P < .001) IV antibiotic DOT (Table 2; Figure 3). This difference persisted after adjustment for SIRS criteria and LOS (Table 3). However, PCT level had no effect on inpatient DOT (P = .098) or total antibiotic DOT (P = .160). Furthermore, PCT level had no effect on use of antibiotics at discharge (P = .906), 30-day mortality (P = .747), or readmission rates (P = .237).

**Discussion**

During the introduction of PCT-guided therapy at our large academic hospital, patients admitted with AECOPD had PCT sent infrequently (31%), and those tested had higher acuity (SIRS, ICU) requiring longer admissions. Even after adjusting for these patient factors, PCT-tested patients received more inpatient DOT and there was no difference in overall DOT when compared with patients without PCT testing. Importantly, there was a 25.5% reduction in IV DOT after adjusting for LOS and SIRS. There was no difference in 30-day readmission or mortality.

Our results are contrary to many prior randomized controlled trials and prospective studies showing PCT-guided
therapy decreases antibiotic utilization in respiratory illness.\textsuperscript{15-17,19,24,25} The discordant results are likely due to differences in guideline compliance; patients in prior studies were either randomized\textsuperscript{16,17,19} or required to have PCT testing on admission with a qualifying diagnosis.\textsuperscript{15,24,25} This bypasses the reality of provider-driven decision making. When given a choice, our results show that providers sent PCT infrequently, usually on patients with more severe disease. A possible explanation for this may be a greater awareness of PCT’s role in sepsis and ICU settings\textsuperscript{26-31} or mistrust in the reported test sensitivity. It could be the medical provider’s tendency to send more tests on sicker patients.\textsuperscript{32} Irrespective of the cause, our results suggest that providers sent PCT to confirm an already high clinical suspicion for bacterial infection rather than using it as a tool to delineate bacterial infection from nonbacterial causes.

Table 1. Characteristics and outcomes of patients with/without PCT measurement during their inpatient admission for AECOPD.

| CHARACTERISTIC                  | PCT MEASURED, N (%) OR MEAN ± SD | NO PCT MEASURED, N (%) OR MEAN ± SD | P  |
|--------------------------------|----------------------------------|-------------------------------------|----|
| Total subjects                 | 73 (31)                          | 165 (69)                            |    |
| Male                           | 32 (44)                          | 82 (50)                             | .404|
| Age (years)\textsuperscript{a} | 68 ± 12.0                        | 66 ± 12.4                           | .534|
| SIRS                           | 45 (62)                          | 70 (42)                             | .012|
| ICU                            | 14 (19)                          | 16 (10)                             | .042|
| Prior PFTs                     | 50 (68)                          | 110 (67)                            | .782|
| FEV1 (L)                       | 1.24 ± 0.53                      | 1.28 ± 0.60                         | .624|
| GOLD class >3                  | 26 (35)                          | 43 (26)                             | .134|
| AECOPD in previous year        | 29 (40)                          | 59 (36)                             | .559|
| Home oxygen use                | 40 (55)                          | 58 (35)                             | .005|

Outcomes

| Received antibiotics           | 64 (87)                          | 107 (65)                            | .001|
| Inpatient antibiotic DOT\textsuperscript{a} | 2.8 ± 1.8                        | 2 ± 1.4                             | <.001|
| Total antibiotic DOT\textsuperscript{a} | 4.3 ± 4.0                        | 3.7 ± 4.1                           | .14 |
| Received IV antibiotics        | 35 (48)                          | 42 (25)                             | .001|
| IV antibiotic DOT\textsuperscript{a} | 3.3 ± 2.2                        | 2.9 ± 1.9                           | .001|
| Antibiotics at discharge       | 31 (42)                          | 78 (47)                             | .493|
| LOS (days)\textsuperscript{a}  | 5.4 ± 3.8                        | 3.1 ± 3.3                           | <.001|
| Readmission (30 days)\textsuperscript{b} | 15 (21)                          | 58 (36)                             | .026|
| Mortality (30 days)            | 6 (8)                            | 6 (4)                               | .147|

Abbreviations: AECOPD, acute exacerbation COPD; DOT, days of therapy; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICU, intensive care unit; IV, intravenous; LOS, length of stay; PCT, procalcitonin; PFT, pulmonary function testing; SIRS, systemic inflammatory response syndrome.

Note: Bold values are considered statistically significant (P < 0.05).

\textsuperscript{a}P value calculated using regression on the log transform of the variable.

\textsuperscript{b}Loss of statistical significance (P = .51) after adjusting for LOS.

Figure 2. Patients with or without PCT measured versus log total antibiotic DOT. DOT indicates days of therapy; PCT, procalcitonin.
Our findings are concordant with the recent ProACT study, an open-label randomized controlled trial of PCT-guided therapy across 14 US hospitals of 1664 patients with lower respiratory tract infection (LRTI), 32% of which had AECOPD. This trial found no decrease in antibiotic DOT between the PCT measurement and usual care. Similar to our study, clinicians’ adherence to PCT guidelines was poor (49.2% for COPD diagnoses) and a significant portion of patients with low PCT still received antibiotics. Our findings, together with ProACT, highlight the challenges with implementation of a PCT-driven model and suggest that achieving a PCT-driven decrease in antibiotic DOT requires high adoption rates for initial measurement and subsequent guideline-based therapy.

Regional differences are likely playing a significant role toward our results. In AECOPD, the sentinel study showing a benefit of PCT-guided therapy (ProCOLD) was conducted in Switzerland, and a meta-analysis has shown a similar benefit in 8 trials conducted outside of North America. Our study examined an academic institution in the United States, with a population and provider culture more similar to studies that failed to show PCT benefit for AECOPD: the ProACT trial and a recent database review utilizing patients across 500 U.S. hospitals. The reason for regional differences in PCT benefit likely ties back into guideline compliance. In the largest study examining PCT use in LRTI outside of trial settings, compliance was 76% in Switzerland and 74% in France, but only 34% in the United States. The provider compliance in our study—with 31% of patients having an initial PCT—is concordant to these findings. Procalcitonin compliance may be higher in European countries due to greater familiarity with PCT-guided therapy and a difference in the health care culture surrounding guidelines; for example, compared with the United States, European guidelines are more likely to have implementation tools to help providers.

Despite poor guideline compliance and minimal effect on total antibiotic DOT, we found a 25.5% decrease in IV antibiotic DOT if PCT result was low. This persisted after adjustment for differences in patient acuity. Although a low result is highly suggestive of nonbacterial infection and the algorithm discourages antibiotics, providers were more comfortable “stepping-down” therapy from IV to oral. The utility of this is debatable, but any decrease in broad spectrum antibiotics is welcome from a stewardship perspective and is associated with less antimicrobial resistance. Furthermore, with no difference in readmission or mortality between groups, testing is unlikely to cause harm.

A major strength of our study is our large cohort in a real-world setting, where consecutively admitted patients with AECOPD were all eligible for inclusion. Our cohort is larger than the randomized trial AECOPD arms and similar in size to the largest retrospective studies on PCT and antibiotics in AECOPD. To reduce confounding from facilities making antibiotic decisions without the option of sending PCT, we excluded patients transferred from outside facilities. To fully characterize the cohort, we included important COPD baseline disease factors such as PFTs, oxygen use, and recent AECOPD. Our study has several limitations. First, we used a retrospective cohort of AECOPD patients based off ICD-9-coded admission diagnoses. To ameliorate misclassification, we confirmed each patient’s diagnosis through extensive chart review, but it is possible that some admissions for AECOPD were not

Table 2. Selected unadjusted analysis of IV antibiotic DOT.

| VARIABLE                | ESTIMATE (STANDARD ERROR) | % CHANGE | P       |
|-------------------------|---------------------------|----------|---------|
| Age                     | +0.002 (0.001)            | +0.2%    | .247    |
| PCT measured            | +0.13 (0.039)             | +13.8%   | .001    |
| PCT low (< 0.25 ng/mL)  | -0.318 (0.086)            | -27.2%   | <.001   |
| LOS                     | +0.157 (0.020)            | +17.0%   | <.001   |
| SIRS                    | +0.076 (0.019)            | +7.9%    | <.001   |

Abbreviations: PCT, procalcitonin; LOS, length of stay in days; SIRS, systemic inflammatory response syndrome; DOT, days of therapy.

Figure 3. PCT level versus log total antibiotic DOT. Low PCT ≤0.25 ng/mL. DOT indicates days of therapy; PCT, procalcitonin.

Our findings are concordant with the recent ProACT study, an open-label randomized controlled trial of PCT-guided therapy across 14 US hospitals of 1664 patients with lower respiratory tract infection (LRTI), 32% of which had AECOPD. This trial found no decrease in antibiotic DOT between the PCT measurement and usual care. Similar to our study, clinicians’ adherence to PCT guidelines was poor (49.2% for COPD diagnoses) and a significant portion of patients with low PCT still received antibiotics. Our findings, together with ProACT, highlight the challenges with implementation of a PCT-guided model and suggest that achieving a PCT-driven decrease in antibiotic DOT requires high adoption rates for initial measurement and subsequent guideline-based therapy.

Regional differences are likely playing a significant role toward our results. In AECOPD, the sentinel study showing a benefit of PCT-guided therapy (ProCOLD) was conducted in Switzerland, and a meta-analysis has shown a similar benefit in 8 trials conducted outside of North America. Our study examined an academic institution in the United States, with a population and provider culture more similar to studies that failed to show PCT benefit for AECOPD: the ProACT trial and a recent database review utilizing patients across 500 U.S. hospitals. The reason for regional differences in PCT benefit likely ties back into guideline compliance. In the largest study examining PCT use in LRTI outside of trial settings, compliance was 76% in Switzerland and 74% in France, but only 34% in the United States. The provider compliance in our study—with 31% of patients having an initial PCT—is concordant to these findings. Procalcitonin compliance may be higher in European countries due to greater familiarity with PCT-guided therapy and a difference in the health care culture surrounding guidelines; for example, compared with the United States, European guidelines are more likely to have implementation tools to help providers.

Despite poor guideline compliance and minimal effect on total antibiotic DOT, we found a 25.5% decrease in IV antibiotic DOT if PCT result was low. This persisted after adjustment for differences in patient acuity. Although a low result is highly suggestive of nonbacterial infection and the algorithm discourages antibiotics, providers were more comfortable “stepping-down” therapy from IV to oral. The utility of this is debatable, but any decrease in broad spectrum antibiotics is welcome from a stewardship perspective and is associated with less antimicrobial resistance. Furthermore, with no difference in readmission or mortality between groups, testing is unlikely to cause harm.

A major strength of our study is our large cohort in a real-world setting, where consecutively admitted patients with AECOPD were all eligible for inclusion. Our cohort is larger than the randomized trial AECOPD arms and similar in size to the largest retrospective studies on PCT and antibiotics in AECOPD. To reduce confounding from facilities making antibiotic decisions without the option of sending PCT, we excluded patients transferred from outside facilities. To fully characterize the cohort, we included important COPD baseline disease factors such as PFTs, home oxygen use, and recent AECOPD, which allowed determination of GOLD classification in the majority of patients. Our study has several limitations. First, we used a retrospective cohort of AECOPD patients based off ICD-9-coded admission diagnoses. To ameliorate misclassification, we confirmed each patient’s diagnosis through extensive chart review, but it is possible that some admissions for AECOPD were not...
In patients admitted with AECOPD, introduction of PCT-guided therapy was poorly adopted and was not associated with the antibiotic reducing effects seen in previous controlled trials. Our study highlights the difficulty with PCT implementation, as providers tested primarily higher acuity AECOPD patients requiring a longer LOS. Even after adjusting for these patient factors, PCT testing did not associate with a decrease in overall antibiotic DOT. However, patients with a low PCT received 25.5% less IV antibiotic DOT, suggesting comfort with stepping-down therapy and a possible benefit from an antimicrobial standpoint.

**Authors’ Note**  
The abstract of this paper was presented at the Infectious Disease Society of America national meeting “IDWeek,” October 8-12, 2014, in Philadelphia, PA.

**Author Contributions**  
RJU contributed to the design of the study, data collection, primary statistical analysis, drafting of the manuscript, manuscript revisions, and approval of the final manuscript. DM contributed to the conception and design of the study and manuscript revisions. SAF contributed to the conception and design of the study and manuscript revisions. KR contributed to the conception and design of the study, primary and advanced statistical analysis, and manuscript revision.

**Data Availability**  
All data contributing to this manuscript are available by request to the corresponding author.

**ORCID iD**  
Robert J Ulrich https://orcid.org/0000-0002-3217-5062

### REFERENCES

1. Murphy SL, Kochanek KD, Xu J, Arias E. Mortality in the United States, 2014. Website. https://www.cdc.gov/nchs/data/databriefs/db229.pdf. NCHS Data Brief. Published December 2015:1-8.

2. Tillet T, Dillon C, Paulose-Ram R, Haizdo E, Doney B. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010. Respir Res. 2013;14:103.

3. Vedroth J, Hudc SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347-365.

4. Pretto JJ, McDonald VM, Wark PA, Hensley MJ. Multicentre audit of inpatient management of acute exacerbations of chronic obstructive pulmonary disease: comparison with clinical guidelines. Intens Med J. 2012;42:380–387.

---

**Table 3. Adjusted multivariable analysis of IV antibiotic DOT.**

| VARIABLE             | ESTIMATE A LOG DOT (STANDARD ERROR) | % CHANGE | P       |
|----------------------|-------------------------------------|----------|---------|
| PCT low (<=0.25 ng/mL) | -0.295 (0.086)                      | -25.5%   | <.001   |
| Log(LOS)             | +0.108 (0.057)                      | +11.4%   | .061    |
| SIRS                 | -0.138 (0.073)                      | -12.9%   | .064    |

**Abbreviations:** DOT, days of therapy; IV, intravenous; LOS, length of stay in days; PCT, procalcitonin; SIRS, systemic inflammatory response syndrome.
5. Lindenaus PK, Pekow P, Gao S, Crawford AS, Gutierrez B, Benjamin EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med.* 2006;144:894–903.

6. Vollweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhahn MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2013;7:CD00257.

7. Papi A, Bellietto CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. *Am J Respir Crit Care Med.* 2006;173:1114–1121.

8. Hawkey PM, Jones AM. The changing epidemiology of resistance. *J Antimicrob Chemother.* 2007;59:15–20.

9. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of *Streptococcus pneumoniae* to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. *N Engl J Med.* 1999;341:233–239.

10. Lee HY, Chen CL, Liu SY, Yan YS, Chang CJ, Chiu CH. Impact of molecular epidemiology and reduced susceptibility to glycopeptides and daptomycin on outcomes of patients with methicillin-resistant *Staphylococcus aureus* bacteremia. *PLoS ONE.* 2015;10:e0136171.

11. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in *Streptococcus pneumoniae* and *Streptococcus pyogenes*. *Emerg Infect Dis.* 2004;10:514–517.

12. Lessa FC, Mu Y, Bamberg WM, et al. Burden of *Clostridium difficile* infection in the United States. *N Engl J Med.* 2015;372:825–834.

13. Kelly CP, Pothoulakis C, LaMont JT. *Clostridium difficile* colitis. *Clin Infect Dis.* 2011;53:45–54.

14. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. *J Clin Endocrinol Metab.* 2004;89:1512–1525.

15. Bifulkel M, Gatta G, Redi C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. *Chest.* 2011;139:1410–1418.

16. Schuetz P, Christ-Crain M, Thammom R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. *JAMA.* 2009;302:1059–1066.

17. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Procalcitonin-guided antibiotic treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded intervention trial. *Lancet.* 2004;363:600–607.

18. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotic therapy in acute respiratory tract infections. *Cochrane Database Syst Rev.* 2012;9:CD007498.

19. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guided therapy with standard therapy. *Chest.* 2007;131:9–19.

20. Mavroudiakos AG, Chatzinikolaidou-Grigoriadou V, Corleautea A, Vetbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. *Eur Respir Rev.* 2017;26:143.

21. Schuetz P, Bulk R, Briel M, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infection: a US health system perspective. *Clin Chem Lab Med.* 2015;53:583–592.

22. Statistics NCH: International classification of diseases, ninth revision, clinical modification (ICD-9). Website. https://www.cdc.gov/nchs/icd/icd9cm.htm.

23. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis *Critical Care Medicine.* 864–874;199206.

24. Schuetz P, Ratschigor M, Dusumend F, et al. Effectiveness of a procalcitonin-guided algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. *Eur J Clin Microbiol Infect Dis.* 2010;29:269–277.

25. Albrich WC, Dusumend F, Buecher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”. *Lancet.* 2008;6:1059–1066.